Home > Cardiology > ESC 2022 > Dapagliflozin DELIVERs for HFmrEF/HFpEF

Dapagliflozin DELIVERs for HFmrEF/HFpEF

Presented By
Prof. Scott Solomon, Brigham and Women's Hospital, Harvard Medical School, MA, USA
ESC 2022
Phase 3, DELIVER
The SGLT2 inhibitor dapagliflozin reduced the risk of cardiovascular death or worsening heart failure in heart failure patients with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF), results of the DELIVER trial indicated. The phase 3 DELIVER trial (NCT03619213) aimed to determine whether dapagliflozin would decrease cardiovascular morbidity and mortality in patients with HFmrEF/HFpEF, a group for whom limited therapies are currently available [1]. At last year’s ESC Congress, the only other large trial in this population, EMPEROR-Preserved, reported a reduction in cardiovascular death or heart failure hospitalisation for patients treated with empagliflozin [2]. Previously, dapagliflozin has been shown to be effective in heart failure patients with reduced ejection fraction [3]. According to Prof. Scott Solomon (Brigham and Women's Hospital, Harvard M...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on